Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management. Its products include joint-replacement implants, surgical robotics and enabling technologies, arthroscopy equipment, sports-medicine repair products, wound dressings, negative-pressure wound-therapy systems and products designed to support tissue healing.

Smith & Nephew serves hospitals, surgeons and other healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions. The company is headquartered in Watford, England, and its ordinary shares are listed in London, while its American Depositary Shares trade on the New York Stock Exchange under the symbol SNN.

Smith & Nephew is led by Chief Executive Officer Deepak Nath, who joined the company in 2022. Its global portfolio includes established brands and technologies used in orthopaedic reconstruction, minimally invasive surgery and wound care.

Key Stats

• Today's Range: $29.60 to $30.27
• 50-Day Range: $26.45 to $30.86
• 52-Week Range: $26.12 to $37.09
• Volume: 1.75 million shs
• Average Volume: 1.20 million shs
• Market Capitalization: $12.67 billion
• P/E Ratio: N/A
• Dividend Yield: 1.95%
• Price Target: $31.91
• Consensus Rating: Hold

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 44% of companies evaluated by MarketBeat, and ranked 689th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 9 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Smith & Nephew SNATS is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Smith & Nephew SNATS has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.45%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 6.45% in the coming year, from $2.17 to $2.31 per share.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.97% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 13.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 1.95%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 25.54% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for SNN on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

25.64% of the stock of Smith & Nephew SNATS is held by institutions.

Company Calendar

• Last Earnings: 11/17/2014
• Record date for 11/6 Dividend: 10/02/2026
• Ex-Dividend for 11/6 Dividend: 10/02/2026
• Today: 11/03/2026
• Dividend Payable: 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 16,988
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $31.91
• High Price Target: $33.88
• Low Price Target: $30.00
• Potential Upside/Downside: +5.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.10
• P/E Growth: 1.67
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.14
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $6.30 billion
• Price / Sales: 2.01
• Cash Flow: $3.45 per share
• Price / Cash Flow: 8.78
• Book Value: $12.45 per share
• Price / Book: 2.43

Miscellaneous

• Outstanding Shares: 418,716,000
• Free Float: 414,529,000
• Market Cap: $12.67 billion
• Optionable: Optionable
• Beta: 0.53